Suchen
Lantheus Holdings Inc
LNTHZur Watchlist hinzufügen
99.640USD
-1.360-1.35%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
6.48BMarktkapitalisierung
23.57KGV TTM
mehr Informationen über Lantheus Holdings Inc Unternehmen
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Lantheus Holdings Inc Informationen
BörsenkürzelLNTH
Name des UnternehmensLantheus Holdings Inc
IPO-datumJun 25, 2015
CEOMarkison (Brian A)
Anzahl der mitarbeiter808
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse331 Treble Cove Road
StadtNORTH BILLERICA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01862
Telefon19786718001
Websitehttps://www.lantheus.com/
BörsenkürzelLNTH
IPO-datumJun 25, 2015
CEOMarkison (Brian A)
Führungskräfte von Lantheus Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
4.70K
+88.02%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
663.52K
-0.18%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
180.68K
-28.64%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-46.09%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
37.34K
+11.08%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
24.58K
+15.28%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
11.50K
+35.98%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Lantheus Holdings Inc?
Die fünf größten Anteilseigner von Lantheus Holdings Inc sind: Ms. Mary Anne Heino
Wie viele Institutionen halten Anteile an Lantheus Holdings Inc (LNTH)?
Mit Stand vom 2026Q1 halten 1043 Institutionen Anteile an Lantheus Holdings Inc, mit einem Gesamtmarktwert von etwa 77.80M, was 119.49% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -5936003.00 gestiegen.